<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354456</url>
  </required_header>
  <id_info>
    <org_study_id>DicleU</org_study_id>
    <nct_id>NCT02354456</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation in Turkey: Epidemiologic Registry-2</brief_title>
  <acronym>AFTER-2</acronym>
  <official_title>An Epidemiological Study to Evaluate the Use of Vitamin K Antagonists and New Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients in Turkey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dicle University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dicle University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is one of the most common cause of preventable ischemic stroke and
      associated with increased cardiovascular morbidity and mortality. Our previous AFTER study
      demonstrated the general epidemiological data about the patients with valvular and
      nonvalvular AF in Turkey. However, data is lacking about the use of new oral anticoagulants
      (NOACs), time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management
      modality in our country. In this multicenter trial the investigators aimed to analyze, follow
      and evaluate the epidemiological data in non-valvular AF patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the most common cause of preventable stroke and strongly
      associated with increased cardiovascular morbidity and mortality with a prevalence of 1-2% in
      general population.The first multicenter trial in AF patients in our country, Atrial
      Fibrillation in Turkey: Epidemiologic Registry (AFTER) study, showed that 40% of non-valvular
      AF patients were on warfarin therapy with an effective INR rate of 37% and the most frequent
      cause of warfarin underuse was physician neglect. Yet, the use of new oral anticoagulants,
      time in therapeutic INR range (TTR) in warfarin users and the main management modality
      (rhythm or rate control) in AF patients have not been studied in Turkey. Therefore, in this
      multicenter trial, we aimed to assess the extent of effective anticoagulant use (by means of
      TTR) and epidemiological characteristics of the nonvalvular AF patients with the use of new
      oral anticoagulants (NOACs) in clinical practice in addition to increased awareness provided
      by AFTER study.

      AFTER-2 study is planned as a prospective, observational and multicenter study with a 6 month
      and 1-year follow-up of the patients. A total of 4100 patients in 42 centers reflecting the
      population of the twelve regions of our country according to the Nomenclature of Territorial
      Units for Statistics will be included in the study.

      The detailed characteristics of the patients with non-valvular AF, the rates and kind of oral
      anticoagulant use, the effect of increased awareness and NOACs on anticoagulant use rate, TTR
      in warfarin using patients and the bleeding risks of the patients will be determined in this
      study. At the end of the study, we will question the patients in terms of major adverse
      events and analyze the independent predictors of these events.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Number of dead patients</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with stroke</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with major haemorrhage</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of hospitalization</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with time in therapeutic INR range</measure>
    <time_frame>1 year</time_frame>
    <description>Time in therapeutic INR range calculated according to Rosendaal method</description>
  </secondary_outcome>
  <enrollment type="Anticipated">4100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        nonvalvular atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All consecutive adult non-valvular AF patients applied to the cardiology clinics with
             at least one attack of AF identified on electrocardiography without rheumatic mitral
             valve stenosis and prosthetic valve disease

        Exclusion Criteria:

          -  Patients who will refuse to be a participant or will not sign the consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faruk Ertas, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dicle University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faruk Ertas, Assoc. Prof.</last_name>
    <phone>00904122488001</phone>
    <phone_ext>1126</phone_ext>
    <email>farukertas@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hasan Kaya, Assoc. Prof.</last_name>
    <phone>00904122488001</phone>
    <phone_ext>1120</phone_ext>
    <email>dr_hasankaya@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dicle Üniversity School of Medicine</name>
      <address>
        <city>Diyarbakir</city>
        <zip>21280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdulkadir Yildiz, Ass. Prof.</last_name>
      <phone>00905052360548</phone>
      <email>drakadiryildiz@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Kaya H, Ertaş F, Kaya Z, Kahya Eren N, Yüksel M, Köroğlu B, Köse N, Yıldız A, Cimen T, Ulgen MS. Epidemiology, anticoagulant treatment and risk of thromboembolism in patients with valvular atrial fibrillation: Results from Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER). Cardiol J. 2014;21(2):158-62. doi: 10.5603/CJ.a2013.0085. Epub 2013 Jun 25.</citation>
    <PMID>23799558</PMID>
  </reference>
  <reference>
    <citation>Ertas F, Eren NK, Kaya H, Aribas A, Acar G, Kanadasi M, Gedik S, Oylumlu M, Yuksel M, Ulgen MS; AFTER Investigators. The atrial fibrillation in Turkey: Epidemiologic Registry (AFTER). Cardiol J. 2013;20(4):447-52. doi: 10.5603/CJ.a2013.0055. Epub 2013 May 15.</citation>
    <PMID>23677730</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013 Jul 16;128(3):237-43. doi: 10.1161/CIRCULATIONAHA.112.001139. Epub 2013 Jun 14.</citation>
    <PMID>23770747</PMID>
  </reference>
  <reference>
    <citation>Yamashita T, Inoue H, Okumura K, Atarashi H, Origasa H; J-RHYTHM Registry Investigators. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM Registry analysis. J Cardiol. 2015 Mar;65(3):175-7. doi: 10.1016/j.jjcc.2014.07.013. Epub 2014 Aug 26.</citation>
    <PMID>25169015</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dicle University</investigator_affiliation>
    <investigator_full_name>Hasan Kaya</investigator_full_name>
    <investigator_title>Associate Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>epidemiology</keyword>
  <keyword>antiocaogulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

